The Center for Medicare and Medicaid Innovation today announced a new payment model for Medicare Part D and Medicare Advantage drug plans beginning January 2020, which will test new incentives for plans, patients and providers to choose drugs with lower list prices. Plans participating in the voluntary five-year model will take on greater risk for spending in the catastrophic phase of Part D and share in any resulting savings to federal reinsurance subsidy costs. The model also includes a Part D rewards and incentives program and other tools to help plans control drug costs and enrollees choose drugs with lower list prices. Also today, the Centers for Medicare & Medicaid Services announced changes to the MA Value-Based Insurance Design model for calendar year 2020, which will allow plans to provide reduced cost sharing and additional supplemental benefits to enrollees based on condition and/or socioeconomic status; bolster rewards and incentives for beneficiaries to improve their health; and increase access to telehealth services. 
 

Headline
The Centers for Medicare & Medicaid Services and the Food and Drug Administration April 23 announced a new pathway to expedite access to certain FDA-…
Blog
Public
In think‑tank reports, like the one released this week by Paragon Health Institute, hospitals are often reduced to abstractions — payment rates, charts,…
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
As published April 20, the Department of Justice released an interim final rule in the Federal Register to delay compliance dates for states and local…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The AHA today released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and…